Associate Principal Scientist
Merck & Co., Inc.
Rahway, New Jersey
Dr. Jiaying Liu is currently an associate principal scientist in Sterile & Specialty Dosage department, i.e.,SSP, in Merck & Co. Inc, leading drug product development of various biologics modalities and small molecule long-acting injectables for subcutaneous delivery. She got her PhD degree in biomedical engineering from Georgia Institute of Technology and Emory University, where she studied novel nano/microparticulate systems of polymers or inorganic material for delivery of nucleic acids, protein and adjuvants for gene therapy and cancer vaccines, which resulted in many publications in peer-reviewed journals and patents. Prior to joining SSP, she started in Merck in Oral Formulation Sciences Department in 2019 and has since led and contributed to the development of many oral drug products, including two that are already FDA approved, Welireg for VHL disease, and Monulpiravir, the oral anti-COVID-19 capsules. Her experience in various therapeutic areas and dosage forms have made her super passionate about novel excipients that modulate the pharmacokinetics, stability and properties of formulations and applying them on innovative drug delivery approaches. She has been leading such research in Merck and also actively driving discussions and collaborations in this field as the secretary and the incoming vice chair of AAPS Excipient Community.
Disclosure information not submitted.
Speaker Spotlight: Emerging Standards and Iterative Approaches to Novel Excipients
Tuesday, October 22, 2024
2:30 PM – 3:30 PM MT